Antigen specificity of antihistone antibodies in connective tissue disease patients with anti-U1RNP antibodies

Springer Science and Business Media LLC - Tập 28 - Trang 113-119 - 2007
Takamasa Wayaku1, Minoru Hasegawa1, Kenzo Kaji1, Miki Kondo1, Yuki Saito1, Hidemitsu Orito1, Mayuka Horikawa1, Takashi Matsushita1, Kazuhiro Komura1, Ikuko Hayakawa1, Yasuhito Hamaguchi1, Fumihide Ogawa2, Manabu Fujimoto1, Kazuhiko Takehara1, Shinichi Sato2
1Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
2Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Tóm tắt

To determine the prevalence of antibodies to individual histone components in collagen disease patients with anti-U1RNP antibodies. Serum samples were examined by enzyme-linked immunosorbent assay. Patients with mixed connective tissue disease (MCTD) and systemic sclerosis (SSc) showed similar levels and patterns of antihistone antibody (AHA) reactivities to individual histones: IgG responses to H2B or H3 and IgM responses to H2B were highest. However, both IgG and IgM AHAs against outer portion of chromatin (H1, H2A, or H2B) were generally higher in SLE compared with other diseases. SLE or SSc patients with anti-U1RNP antibodies showed generally higher AHA levels than in those without them. Thus, the pattern of reactivities to each histone component was dependent on the disease, while the intensity was dependent on both the disease and anti-U1RNP antibodies. The antigenic stimulus in SLE may be different from other connective tissue diseases and is more likely to be native chromatin.

Tài liệu tham khảo

Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR (1972) Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52:148–159 Smolen JS, Steiner G (1998) Mixed connective tissue disease: to be or not to be. Arthritis Rheum 41:768–777 Sharp GC, Irvin WS, May CM, Holman HR, McDuffie FC, Hess EV, Schmid FR (1976) Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systemic lypus erythematosus and other rheumatic diseases. New Eng J Med 295:1149–1154 Lemmer JP, Curry NH, Mallory JH, Waller MV (1982) Clinical characteristics and course in patients with high titer anti-RNP antibodies. J Rheumatol 9:536–542 Munves EF, Shur PH (1983) Antibodies to Sm and RNP: prognosticators of disease involvement. Arthritis Rheum 26:848–853 Gaudreau A, Amor B, Kahn MF, Ryckewaert A, Sany J, Peltier AP (1978) Clinical significance of antibodies to soluble extractable nuclear antigens (anti-ENA). Ann Rheum Dis 1978:321–327 Reichlin M, Mattioli M (1972) Correlation of a precipitin reaction to an RNAprotein antigen and a low prevalence of nephritis in patients with systemic lupus erythematosus. New Eng J Med 286:908–911 Reichlin M (1976) Problems in differentiating SLE and mixed connective-tissue disease. New Eng J Med 295:1194–1195 Nimelstein SH, Brody S, Mcshane D, Holman HR (1980) Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine 59:239–248 Notman DD, Kurata N, Tan EM (1975) Profiles of antinuclear antibodies in systemic rheumatic diseases. Ann Intern Med 83:464–469 Lazaro MA, Maldonado Cocco JA, Catoggio LJ, Babini SM, Messina OD, Morteo OG (1989) Clinical and serologic characteristics of patients with overlap syndrome: is mixed connective tissue disease a distinct clinical entity? Medicine 68:58–65 Combe B, Rucheton M, Graafland H, Lussiez V, Brunel C, Sany J (1989) Clinical significance of anti-RNP and anti-Sm autoantibodies as determined by immunoblotting and immunoprecipitation in sera from patients with connective tissue diseases. Clin Exp Immunol 75:18–24 Fritzler MJ, Tan EM (1978) Antibodies to histones in drug-induced and idiopathic lupus erythematosus. J Clin Invest 62:560–567 Aitcheson CT, Peebles C, Joslin F, Tan EM (1980) Characteristics of antinuclear antibodies in rheumatoid arthritis. Reactivity of rheumatoid factor with a histone-dependent nuclear antigen. Arthritis Rheum 23:528–538 Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K (1994) Antigen specificity of antihistone antibodies in localized scleroderma. Arch Dermatol 130:1273–1277 Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K (1994) Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol 31:567–571 Kubo M, Ihn H, Yazawa N, Sato S, Kikuchi K, Tamaki K (1999) Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis. J Invest Dermatol 112:711–715 Portanova JP, Rubin RL, Joslin FG, Agnello VD, Tan EM (1982) Reactivity of anti-histone antibodies induced by procainamide and hydralazine. Clin Immunol Immunopathol 25:67–79 Gohill J, Cary PD, Couppez M, Fritzler MJ (1985) Antibodies from patients with drug-induced and idiopathic lupus erythematosus react with epitopes restricted to the amino and carboxyl termini of histone. J Immunol 135:3116–3121 Rubin RL, Waga S (1987) Antihistone antibodies in systemic lupus erythematosus. J Rheumatol Suppl 14(Suppl 13):118–126 Totoritis MC, Tan EM, McNally EM, Rubin RL (1988) Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N Engl J Med 318:1431–1436 Hasegawa M, Sato S, Kikuchi K, Takehara K (1998) Antigen specificity of antihistone antibodies in systemic sclerosis. Ann Rheum Dis 57:470–475 Hirakata M, Okano Y, Pati U, Medsger TA Jr, Hardin JA, Craft J (1993) Identification of autoantibodies to RNA polymerase II: occurrence in systemic sclerosis and association with autoantibodies to RNA polymerase I and III. J Clin Invest 91:2665–2672 Kasukawa R, Tojo T, Miyawaki S (1987) Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds) Mixed connective tissue diseases and antinuclear antibodies. Elsevier, Amsterdam, pp 41–47 Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277 Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Eng J Med 292:403–407 Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Eng J Med 292:344–348 Hardin JA (1986) The lupus autoantigens and the pathogenesis of systemic lupus erythematosus. Arthritis Rheum 29:457–460 Tan EM (1982) Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 33:167–240 Hardin JA, Thomas JO (1983) Antibodies to histones in systemic lupus erythematosus: localization of prominent autoantigens on histones H1 and H2B. Proc Natl Acad Sci USA 80:7410–7414 Kohda S, Kanayama Y, Okamura M, Amatsu K, Negoro N, Takeda T, Inoue T (1989) Clinical significance of antibodies to histones in systemic lupus erythematosus. J Rheumatol 16:24–28 Amoura Z, Chabre H, Koutouzov S, Lotton C, Cabrespines A, Bach JF, Jacob L (1994) Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 37:1684–1688 Mendelson E, Bustin M (1984) Monoclonal antibodies against distinct determinants of histone H5 bind to chromatin. Biochemistry 23:3459–3466